1. Home
  2. MTR vs TLPH Comparison

MTR vs TLPH Comparison

Compare MTR & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTR
  • TLPH
  • Stock Information
  • Founded
  • MTR 1979
  • TLPH 2005
  • Country
  • MTR United States
  • TLPH United States
  • Employees
  • MTR N/A
  • TLPH N/A
  • Industry
  • MTR Oil & Gas Production
  • TLPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • MTR Energy
  • TLPH Health Care
  • Exchange
  • MTR Nasdaq
  • TLPH Nasdaq
  • Market Cap
  • MTR 10.6M
  • TLPH 11.1M
  • IPO Year
  • MTR N/A
  • TLPH 2011
  • Fundamental
  • Price
  • MTR N/A
  • TLPH $1.32
  • Analyst Decision
  • MTR
  • TLPH Strong Buy
  • Analyst Count
  • MTR 0
  • TLPH 1
  • Target Price
  • MTR N/A
  • TLPH $6.00
  • AVG Volume (30 Days)
  • MTR 2.8K
  • TLPH 545.9K
  • Earning Date
  • MTR 01-01-0001
  • TLPH 11-12-2025
  • Dividend Yield
  • MTR 3.24%
  • TLPH N/A
  • EPS Growth
  • MTR N/A
  • TLPH N/A
  • EPS
  • MTR 0.21
  • TLPH N/A
  • Revenue
  • MTR $580,337.00
  • TLPH $27,000.00
  • Revenue This Year
  • MTR N/A
  • TLPH N/A
  • Revenue Next Year
  • MTR N/A
  • TLPH $14,533.26
  • P/E Ratio
  • MTR $24.12
  • TLPH N/A
  • Revenue Growth
  • MTR N/A
  • TLPH N/A
  • 52 Week Low
  • MTR $4.70
  • TLPH $0.38
  • 52 Week High
  • MTR $10.42
  • TLPH $1.45
  • Technical
  • Relative Strength Index (RSI)
  • MTR 32.96
  • TLPH 81.47
  • Support Level
  • MTR $5.12
  • TLPH $0.86
  • Resistance Level
  • MTR $5.34
  • TLPH $1.35
  • Average True Range (ATR)
  • MTR 0.14
  • TLPH 0.09
  • MACD
  • MTR -0.05
  • TLPH 0.02
  • Stochastic Oscillator
  • MTR 0.00
  • TLPH 80.24

About MTR Mesa Royalty Trust

Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: